Comparative Pharmacology
Head-to-head clinical analysis: CLOZARIL versus INVEGA HAFYERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOZARIL versus INVEGA HAFYERA.
CLOZARIL vs INVEGA HAFYERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clozapine is an atypical antipsychotic that binds to multiple receptors including dopamine D1-D5 (with greater affinity for D4), serotonin 5-HT2A, 5-HT2C, 5-HT3, 5-HT6, 5-HT7, histamine H1, muscarinic M1-M5, and adrenergic α1- and α2-receptors. Its therapeutic efficacy is primarily attributed to antagonism of D2 and 5-HT2A receptors. It also has weak D2 antagonism and rapid dissociation from D2 receptors, which may contribute to lower extrapyramidal side effects.
Paliperidone palmitate is an atypical antipsychotic that antagonizes D2 and 5-HT2A receptors, with additional antagonism at alpha2, alpha1, and H1 receptors.
Initial 12.5 mg orally once or twice daily, titrate by 25-50 mg/day over 2 weeks to target 300-450 mg/day in divided doses; max 900 mg/day.
INVEGA HAFYERA (paliperidone palmitate) is dosed once weekly via intramuscular injection in the gluteal or deltoid muscle. The recommended starting dose is 1,092 mg (deltoid or gluteal) or 1,560 mg (gluteal only) on treatment day 1 and day 8, both given in the deltoid muscle. Subsequent maintenance doses are administered once monthly. Note: INVEGA HAFYERA is only for once-weekly administration; once-monthly formulations (INVEGA SUSTENNA) are also available.
None Documented
None Documented
Terminal elimination half-life is approximately 8–12 hours at steady state; range 6–26 hours, increasing with dose due to saturable metabolism.
Terminal elimination half-life is 25-49 days (mean ~36 days) due to slow dissolution from intramuscular depot. Steady-state reached after 4-5 monthly injections.
Approximately 50% excreted renally as metabolites, with less than 1% unchanged; 30% eliminated in feces via biliary excretion.
Primarily renal: 59% of paliperidone excreted unchanged in urine; 32% as metabolites; 6-12% fecal. Biliary excretion is minimal.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic